Blue Trust’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.64K Sell
33
-125
-79% -$12.1K ﹤0.01% 1916
2026
Q2
$12.4K Buy
158
+117
+285% +$7.98K ﹤0.01% 1799
2026
Q1
$2.65K Hold
41
– – ﹤0.01% 2089
2025
Q4
$2.76K Hold
41
– – ﹤0.01% 2095
2025
Q3
$3.01K Sell
41
-5
-11% -$332 ﹤0.01% 2082
2025
Q2
$2.39K Hold
46
– – ﹤0.01% 2112
2025
Q1
$2.94K Buy
+46
New +$2.67K ﹤0.01% 2177
2024
Q4
– Sell
-27
Closed -$1.41K – 2669
2024
Q3
$1.41K Buy
27
+16
+145% +$917 ﹤0.01% 2647
2024
Q2
$447 Buy
+11
New +$482 ﹤0.01% 2623
2023
Q2
– Sell
-46
Closed -$3K – 2232
2023
Q1
$3K Hold
46
– – ﹤0.01% 1919
2022
Q4
$2K Hold
46
– – ﹤0.01% 1927
2022
Q3
$2K Hold
46
– – ﹤0.01% 1785
2022
Q2
$2K Buy
+46
New +$1.99K ﹤0.01% 1655

Other funds holding HALO

Blue Trust's HALO Position: Q3 2026 in Review

Blue Trust reduced its Halozyme (HALO) stake by 79% in Q3 2026, selling an estimated $12.1K and leaving 33 shares worth $3.64K. The position accounts for ﹤0.01% of the portfolio, ranked #1916.

Blue Trust first reported a position in HALO in Q2 2022 and has held it in 13 quarters since. The position peaked at $12.4K in Q2 2026. 662 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Blue Trust held 33 shares of Halozyme worth $3.64K as of Q3 2026.
  • Blue Trust sold 125 Halozyme shares in Q3 2026, an estimated $12.1K.
  • Halozyme made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1916 holding.
  • Blue Trust first reported a position in Halozyme in Q2 2022 and has held it in 13 quarters since.
  • Blue Trust's Halozyme position peaked at $12.4K in Q2 2026.
  • 662 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.